Skip to Main Content

Gilead Sciences said Monday that a large clinical trial of its drug Trodelvy achieved its primary goal of delaying tumor growth in women with the most common form of breast cancer.

But Gilead chose not to provide any specific data from the study. It would also not even say whether the Trodelvy study results were clinically meaningful for women with HR-positive, HER2-negative breast cancer, despite reaching statistical significance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment